Interpretation of Chinese consensus on autologous hematopoietic stem cell transplantation for adult acute leukemia(2024)
-
摘要: 自体造血干细胞移植是成人急性白血病缓解后的治疗方法之一，但在我国成人急性白血病患者治疗中应用较少。为提高临床医师对自体造血干细胞移植在成人急性白血病治疗中作用和地位的认识，中华医学会血液学分会造血干细胞应用学组参考国内外最新指南和文献，荟萃国内外最新研究成果，共同制定了《中国成人急性白血病自体造血干细胞移植专家共识(2024年版)》。文章拟对该共识重点部分进行解读，以期更好地指导临床实践。Abstract: Autologous hematopoietic stem cell transplantation(auto-HSCT) represents a notable therapeutic modality for adult acute leukemia(AL) post-remission. Nonetheless, the utilization of auto-HSCT among adult AL patients in China currently remains limited. In a bid to bolster comprehension among clinicians regarding the pivotal role and significance of auto-HSCT in adult AL management, the Stem Cell Application Group of Chinese Society of Hematology have referred to the latest guidelines and literature both domestically and internationally, and have compiled the latest research findings from around the world to jointly formulate the "Chinese consensus on autologous hematopoietic stem cell transplantation for adult acute leukemia(2024)". To better guide clinical practice, this article intends to interpret the key parts of the consensus.
-
-
[1] Nagler A, Galimard JE, Labopin M, et al. Autologous stem cell transplantation(ASCT)for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT[J]. Cancer Med, 2023, 12(2): 1482-1491. doi: 10.1002/cam4.5039
[2] Yu S, Fan Z, Ma L, et al. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes[J]. JAMA Netw Open, 2021, 4(7): e2115991. doi: 10.1001/jamanetworkopen.2021.15991
[3] Yu S, Lin T, Nie D, et al. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes[J]. Blood Cancer J, 2021, 11(12): 195. doi: 10.1038/s41408-021-00591-4
[4] 中华医学会血液学分会, 中国医师协会血液科医师分会. 中国急性早幼粒细胞白血病诊疗指南(2018年版)[J]. 中华血液学杂志, 2018, 39(3): 179-183.
[5] Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet[J]. Blood, 2009, 113(9): 1875-1891. doi: 10.1182/blood-2008-04-150250
[6] Wang M, Zhang H, Zheng X, et al. Comparison of autologous, matched sibling, and alternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study[J]. Hematol Oncol, 2024, 42(1): e3230. doi: 10.1002/hon.3230
[7] Chen J, Labopin M, Pabst T, et al. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT[J]. Bone Marrow Transplant, 2023, 58(12): 1322-1330. doi: 10.1038/s41409-023-02070-9
[8] Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia[J]. Blood, 2019, 134(12): 935-945. doi: 10.1182/blood.2018886960
[9] Zeng Q, Xiang B, Liu Z. Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission[J]. Ann Hematol, 2022, 101(8): 1711-1718. doi: 10.1007/s00277-022-04863-2
[10] Yang F, Ren Q, Zu Y, et al. Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia[J]. Br J Haematol, 2024, 205(2): 645-652. doi: 10.1111/bjh.19597
[11] Burchert A, Bug G, Fritz LV, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation(SORMAIN)[J]. J Clin Oncol, 2020, 38(26): 2993-3002. doi: 10.1200/JCO.19.03345
[12] Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3[J]. J Clin Oncol, 2024, 42(15): 1766-1775. doi: 10.1200/JCO.23.02474
[13] Bewersdorf JP, Allen C, Mirza AS, et al. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis[J]. Transplant Cell Ther, 2021, 27(12): 997. e1-997. e11. doi: 10.1016/j.jtct.2021.09.005
[14] Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial[J]. J Clin Oncol, 2020, 38(36): 4249-4259. doi: 10.1200/JCO.19.03277
[15] Kent A, Schwartz M, McMahon C, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse[J]. Bone Marrow Transplant, 2023, 58(8): 849-854. doi: 10.1038/s41409-023-01987-5
[16] Bug G, Burchert A, Wagner EM, et al. Phase Ⅰ/Ⅱ study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML(PANOBEST trial)[J]. Leukemia, 2017, 31(11): 2523-2525. doi: 10.1038/leu.2017.242
[17] Fathi AT, Kim HT, Soiffer RJ, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies[J]. Blood Adv, 2022, 6(22): 5857-5865. doi: 10.1182/bloodadvances.2022008632
[18] Haroon A, Alfraih F, Hanbali A, et al. Allogeneic transplant compared to pediatric-inspired therapy for Philadelphia chromosome-negative adolescent and adult ALL in first complete remission[J]. Bone Marrow Transplant, 2022, 57(4): 593-597. doi: 10.1038/s41409-022-01595-9
[19] Lv M, Liu L, He Y, et al. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease[J]. Br J Haematol, 2023, 202(2): 369-378. doi: 10.1111/bjh.18846
[20] Ding Z, Han MZ, Chen SL, et al. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China[J]. Chin Med J(Engl), 2015, 128(15): 2065-2071.
[21] Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia[J]. Semin Hematol, 2009, 46(1): 64-75. doi: 10.1053/j.seminhematol.2008.09.003
[22] Giebel S, Labopin M, Potter M, et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT[J]. Eur J Cancer, 2018, 96: 73-81. doi: 10.1016/j.ejca.2018.03.018
[23] 吕梦楠, 姜尔烈, 何祎, 等. 自体与同胞全相合造血干细胞移植治疗Ph+急性淋巴细胞白血病的疗效比较[J]. 中华血液学杂志, 2020, 41(5): 373-378. https://www.cnki.com.cn/Article/CJFDTOTAL-EKYX202302006.htm
[24] 王普, 李彩霞, 张莹, 等. 自体造血干细胞移植治疗T淋巴母细胞淋巴瘤41例临床研究[J]. 中华血液学杂志, 2020, 41(3): 198-203. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201606029.htm
[25] Lyu M, Jiang E, He Y, et al. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Hematology, 2021, 26(1): 65-74. doi: 10.1080/16078454.2020.1868783
[26] Gaballa MR, Banerjee P, Milton DR, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia[J]. Blood, 2022, 139(12): 1908-1919. doi: 10.1182/blood.2021013290
[27] Metheny LL, Sobecks R, Cho C, et al. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia[J]. Blood Adv, 2024, 8(6): 1384-1391. doi: 10.1182/bloodadvances.2023011514
[28] Liu W, Liu W, Zou H, et al. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma[J]. J Immunother Cancer, 2024, 12(4): e008857. doi: 10.1136/jitc-2024-008857
[29] Qiu Y, Wan CL, Xu MZ, et al. Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL[J]. Blood Cancer J, 2023, 13(1): 66. doi: 10.1038/s41408-023-00837-3
[30] Craddock C, Jackson A, Loke J, et al. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia[J]. J Clin Oncol, 2021, 39(7): 768-778. doi: 10.1200/JCO.20.02308
[31] Burnett AK, Russell NH, Hills RK, et al. Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses[J]. J Clin Oncol, 2021, 39(8): 890-901. doi: 10.1200/JCO.20.01170
[32] Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12): 1345-1377. doi: 10.1182/blood.2022016867
[33] de Benito A de S, Jeker B, Gfeller E, et al. Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia[J]. Haematologica, 2020, 105(1): e9-e12. doi: 10.3324/haematol.2019.216457
[34] Lee JM, Park S, Hwang I, et al. FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing[J]. Cancers, 2022, 14(24): 6121. doi: 10.3390/cancers14246121
-
计量
- 文章访问数: 598
- 施引文献: 0
下载: